• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用超高分辨率比较基因组杂交阵列鉴定与胰腺癌侵袭性相关的基因组改变。

Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.

作者信息

Legoffic Aude, Calvo Ezequiel Luis, Barthet Marc, Delpero Jean-Robert, Dagorn Jean Charles, Iovanna Juan Lucio

机构信息

INSERM U.624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, Marseille, France.

出版信息

Pancreatology. 2009;9(3):267-72. doi: 10.1159/000212092. Epub 2009 Apr 29.

DOI:10.1159/000212092
PMID:19407481
Abstract

BACKGROUND

Genomic alterations present in pancreatic adenocarcinoma have been described only partially. In addition, the relations between these alterations and the aggressiveness of the phenotype remain unknown.

METHODS

Genomic DNA and total RNA from 5 pancreatic cell lines, of which 2 have an aggressive phenotype and are gemcitabine-resistant (Mia-Paca2 and Panc-1), and 3 less aggressive and gemcitabine-sensitive (Capan-1, Capan-2 and BxPC3), have been purified. DNA abnormalities have been analyzed using an ultra-high-resolution CGH array and mRNA expression was studied with an Affymetrix GeneChip expression array.

RESULTS

We identified 573 amplified and 30 deleted genes common to all 5 cell lines. Some of them have already been described, whereas other genes, implicated in signal transduction, apoptosis, cell cycle or cell migration, are described for the first time as being related to this cancer. Comparison of genomic abnormalities between the 2 most aggressive and the 3 less aggressive cell lines led to the identification of 368 genes specifically amplified in the aggressive cell lines. However, no specific gene deletion seems to be associated with the aggressive phenotype.

CONCLUSION

Using a high-resolution approach, we could precisely describe the genomic alterations associated with pancreatic adenocarcinoma and determine those associated with an aggressive phenotype.

摘要

背景

胰腺腺癌中存在的基因组改变仅得到部分描述。此外,这些改变与表型侵袭性之间的关系仍不清楚。

方法

已从5种胰腺细胞系中纯化出基因组DNA和总RNA,其中2种具有侵袭性表型且对吉西他滨耐药(Mia-Paca2和Panc-1),3种侵袭性较弱且对吉西他滨敏感(Capan-1、Capan-2和BxPC3)。使用超高分辨率比较基因组杂交阵列分析DNA异常情况,并使用Affymetrix基因芯片表达阵列研究mRNA表达。

结果

我们鉴定出了所有5种细胞系共有的573个扩增基因和30个缺失基因。其中一些基因已被描述过,而其他与信号转导、凋亡、细胞周期或细胞迁移有关的基因则首次被描述与这种癌症相关。比较2种侵袭性最强和3种侵袭性较弱的细胞系之间的基因组异常情况,发现了368个在侵袭性细胞系中特异性扩增的基因。然而,似乎没有特定的基因缺失与侵袭性表型相关。

结论

采用高分辨率方法,我们能够精确描述与胰腺腺癌相关的基因组改变,并确定与侵袭性表型相关的改变。

相似文献

1
Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.使用超高分辨率比较基因组杂交阵列鉴定与胰腺癌侵袭性相关的基因组改变。
Pancreatology. 2009;9(3):267-72. doi: 10.1159/000212092. Epub 2009 Apr 29.
2
Analysis of genomic DNA alterations and mRNA expression patterns in a panel of human pancreatic cancer cell lines.一组人胰腺癌细胞系中的基因组DNA改变和mRNA表达模式分析。
Genes Chromosomes Cancer. 2005 Sep;44(1):37-51. doi: 10.1002/gcc.20216.
3
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.蛋白酶体抑制剂硼替佐米对胰腺癌细胞基因表达谱的影响。
J Surg Res. 2008 Mar;145(1):111-23. doi: 10.1016/j.jss.2007.03.061. Epub 2007 Aug 22.
4
The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.Reg4 基因在胰腺癌发展的早期被扩增,是一个很有前途的治疗靶点。
PLoS One. 2009 Oct 16;4(10):e7495. doi: 10.1371/journal.pone.0007495.
5
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.TM4SF1在体外和体内均可促进胰腺癌对吉西他滨的耐药性。
PLoS One. 2015 Dec 28;10(12):e0144969. doi: 10.1371/journal.pone.0144969. eCollection 2015.
6
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.通过诱导吉西他滨化疗耐药性抑制调控核糖核苷酸还原酶M1和胞苷脱氨酶表达的MiR-608在胰腺癌细胞中的作用。
Cancer Chemother Pharmacol. 2017 Oct;80(4):765-775. doi: 10.1007/s00280-017-3418-2. Epub 2017 Sep 8.
7
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.ZIP4 通过增加转录因子 ZEB1 的表达来促进整合素 α3β1 信号转导并抑制胰腺癌细胞中吉西他滨转运蛋白 ENT1 的表达。
Gastroenterology. 2020 Feb;158(3):679-692.e1. doi: 10.1053/j.gastro.2019.10.038. Epub 2019 Nov 9.
8
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.胰腺腺癌肿瘤的RNA测序产生了与长期生存相关的新表达模式,并揭示了血管生成素样蛋白4(ANGPTL4)的作用。
Mol Oncol. 2016 Oct;10(8):1169-82. doi: 10.1016/j.molonc.2016.05.004. Epub 2016 May 26.
9
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.MUC4 粘蛋白通过协同核苷转运蛋白家族介导人类胰腺癌细胞对吉西他滨的耐药性。
Oncogene. 2013 Mar 28;32(13):1714-23. doi: 10.1038/onc.2012.179. Epub 2012 May 14.
10
Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.沉默胰腺腺癌上调因子(PAUF)可增加胰腺癌细胞对吉西他滨的敏感性。
Tumour Biol. 2016 Jun;37(6):7555-64. doi: 10.1007/s13277-015-4641-2. Epub 2015 Dec 18.

引用本文的文献

1
An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.一种非 ABCG2 底物的抗癌剂 FL118 靶向耐药性癌症干细胞样细胞,并克服了人胰腺癌细胞的治疗抵抗性。
J Exp Clin Cancer Res. 2018 Oct 3;37(1):240. doi: 10.1186/s13046-018-0899-8.
2
Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.间充质样胰腺癌细胞比上皮样胰腺癌细胞更频繁地携带特定的基因组改变。
Mol Oncol. 2014 Oct;8(7):1253-65. doi: 10.1016/j.molonc.2014.04.007. Epub 2014 May 2.
3
Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells.
钛醇盐(OPy)(2)Ti(4AP)(2)对癌细胞集落形成细胞的细胞毒性作用。
Invest New Drugs. 2012 Feb;30(1):114-20. doi: 10.1007/s10637-010-9530-3. Epub 2010 Sep 7.